Tissue Heart Valves (THV) - EPIC™ MAX Clinical data

SURGICAL AORTIC
VALVE SOLUTIONS
TISSUE HEART VALVES (THV)

Our latest aortic valve replacement solution for optimizing key clinical outcomes and the possibilities for patient lifetime management.

BUILT ON THE EPIC™PLATFORM THAT HAS STOOD THE TEST OF TIME

AT 10 YEARS

OVER 11.000 PATIENTS

94.6%*

Epic™ Supra Valve
Freedom From All-Cause
Reintervention²

OVER 1.900 PATIENTS

96.3%*

Epic™ Supra Valve
Freedom from SVD
(Structural Valve Degeneration)
All patient age³

FIND OUT MORE ABOUT:

DOWNLOAD THE EPIC MAX BROCHURE

COMMITED TO VALVE-IN-VALVE* FOLLOW-UP DATA

3-YEAR OUTCOMES OF VALVE-IN-VALVE INTERVENTION IN A U.S. POPULATION

>95.0%

Epic™ Supra Valve
Patients Experienced Freedom
from Valve Intervention⁴

OPTIMIZE OUTCOMES WITH EXCELLENT HEMODYNAMICS

ESTIMATED MEAN PRESSURE GRADIENT AT 1 YEAR FOR EPIC MAX (mm Hg)¹

MEAN PRESSURE GRADIENT PREDICTED BASED ON MATCHED STENT ID FOR BIOCOR/EPIC™ VALVES.

Maximizing the internal orifice provides large effective orifice areas (EOAs) and low gradients to reduce the burden on the heart and contribute to better patient outcomes.

*The safety and effectiveness of valve-in-valve procedures in an Epic™ Max valve has not been established

BRINGING YOU...

Clinical Case clubs | Educational tools | Hot topics
Expert opinions | Live & online discussions

TV

Epic™ HCP testimonial

Epic™ Mitral & Supra Aortic stented tissue valves HCP testimonial

Epic™ Mitral Valve

Epic™ Mitral stented tissue valve with Linx™ AC technology

Webinar 2022: Management of aortic and mitral valve disease

Webinar: Aortic & Mitral Valve Disease

Webinar 2022: Management of aortic and mitral valve disease

EACTS 2022: SMV repair vs replacement

EACTS 2022 Symposium: Surgical Mitral Valve Repair versus Replacement in the Modern Era of Transcatheter Valve Interventions.

References

[a] Biocor IFU [b] Maitland, Andrew, Gregory M. Hirsch, and Edward A. Pascoe. “Hemodynamic Performance of the St. Jude Medical Epic™ Supra Aortic Stented Valve.” Journal of Heart Valve disease 20.3 (2011): 327. [c] Epic Plus IFU
Wiechmann, RJ., et. al. Ten-year Outcomes of Surgical Aortic Valve Replacement with a Contemporary Supra Annular Porcine Valve in a Medicare Population. JTCVS Open. 2022, doi.org/10.1016/j.xjon.2022.08.002.
Lehmann S, Merk DR, Etz CD, Oberbach A, Uhlemann M, Emrich F et al. Porcine xenograft for aortic, mitral and double valve replacement: long-term results of 2544 consecutive patients. Eur J Cardiothorac Surg 2016;49:1150–6.
H. Kenith Fang, et al. Three-Year Outcomes of Valve-in-Valve Intervention within the Epic™ Supra and Epic™ Mitral Valves in a Medicare Population. TVT Conference 2022; Chicago, USA; June 9th, 2022.